Christelle Stamm
Overview
Explore the profile of Christelle Stamm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Jun;
5(7):1130.
PMID: 38886525
No abstract available.
2.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Apr;
5(7):1102-1120.
PMID: 38565920
The YAP-TEAD protein-protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP-TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly...
3.
Tiedt R, King F, Stamm C, Niederst M, Delach S, Zumstein-Mecker S, et al.
Cell Rep
. 2023 Mar;
42(4):112297.
PMID: 36961816
Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not eradicated and eventually relapse. To address these...
4.
Fairhurst R, Knoepfel T, Buschmann N, Leblanc C, Mah R, Todorov M, et al.
J Med Chem
. 2020 Sep;
63(21):12542-12573.
PMID: 32930584
FGF19 signaling through the FGFR4/β-klotho receptor complex has been shown to be a key driver of growth and survival in a subset of hepatocellular carcinomas, making selective FGFR4 inhibition an...
5.
Weiss A, Adler F, Buhles A, Stamm C, Fairhurst R, Kiffe M, et al.
Mol Cancer Ther
. 2019 Aug;
18(12):2194-2206.
PMID: 31409633
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and it is the third leading cause of cancer-related deaths worldwide. Recently, aberrant signaling through the FGF19/FGFR4 axis...
6.
McDonald 3rd E, de Weck A, Schlabach M, Billy E, Mavrakis K, Hoffman G, et al.
Cell
. 2017 Jul;
170(3):577-592.e10.
PMID: 28753431
Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant oncogenes. However, a comprehensive mapping of cancer dependencies has...
7.
Goyal L, Saha S, Liu L, Siravegna G, Leshchiner I, Ahronian L, et al.
Cancer Discov
. 2016 Dec;
7(3):252-263.
PMID: 28034880
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients...
8.
Wohrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, et al.
PLoS One
. 2013 Nov;
8(10):e77652.
PMID: 24204904
Malignant rhabdoid tumors (MRTs) are aggressive pediatric cancers arising in brain, kidney and soft tissues, which are characterized by loss of the tumor suppressor SNF5/SMARCB1. MRTs are poorly responsive to...
9.
Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, et al.
Cancer Discov
. 2012 Sep;
2(12):1118-33.
PMID: 23002168
Unlabelled: Patient stratification biomarkers that enable the translation of cancer genetic knowledge into clinical use are essential for the successful and rapid development of emerging targeted anticancer therapeutics. Here, we...
10.
Harbinski F, Craig V, Sanghavi S, Jeffery D, Liu L, Sheppard K, et al.
Cancer Discov
. 2012 Aug;
2(10):948-59.
PMID: 22874768
The overall power of kinase inhibitors is substantially overshadowed by the acquisition of drug resistance. To address this issue, we systematically assessed the potential of secreted proteins to induce resistance...